Is Wegovy Worth It? An Honest Cost-Benefit Look

"Is Wegovy worth it?" is really three questions wearing one coat: does it work, what does it cost, and does the benefit justify the price for your situation. The honest answer is that the drug works about as well as the trials promised, the cost is genuinely high and recurring, and whether the trade is worth it splits sharply depending on what you are treating. There is no universal yes or no — but there is an honest framework, and that is what this guide gives you. Prices below are dated as of June 2026; treat them as ranges to verify, not quotes. Nothing here is medical or financial advice.

What you get: the benefit, stated honestly

The headline benefit is well-evidenced. In STEP 1, the 68-week pivotal trial, adults with overweight or obesity (without diabetes) on once-weekly semaglutide 2.4 mg lost an average of about 14.9% of body weight, versus roughly 2.4% on placebo¹. That is a large effect for a drug rather than surgery, and it is the number the "worth it" question really turns on. Wegovy's FDA label reflects this: it is approved for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, and in certain adolescents².

But a single percentage hides the spread. Averages are not promises — some people lose far more than 15%, some lose little, and a minority do not respond. And the loss is not free of trade-offs: gastrointestinal side effects (nausea, constipation, diarrhea) are common, especially during dose escalation, and a meaningful share of the weight lost is lean muscle rather than fat. So "worth it" already depends on whether you are likely to be an average responder, a strong one, or a non-responder — something you cannot know until you try it under supervision.

What it costs: high, and recurring

This is where the math gets uncomfortable. Wegovy's published US list price has sat around $1,300–$1,350 for a 28-day supply, and once you factor in that many people pay pharmacy cash prices at or slightly below list before any discount, the real out-of-pocket figure for an unsubsidized buyer often lands in the ~$1,300–$1,600/month range depending on pharmacy and dose timing. Few people pay the sticker — but the routes that lower it are narrow. With commercial insurance that covers Wegovy, the manufacturer savings card can bring eligible patients down to a modest copay; without coverage, Novo Nordisk's NovoCare self-pay vials run around $499/month for brand-name semaglutide. We map every payment route — savings card, NovoCare, GoodRx, and compounded — in Wegovy cost, GoodRx & the cheapest ways without insurance.

The cost that the ads never foreground is the duration. Wegovy is not a 6-month course you finish. Which brings us to the single most important fact for the "worth it" calculation.

The catch that changes the math: you have to keep taking it

The benefit lasts as long as the treatment does. In the STEP 1 trial extension, participants who stopped semaglutide regained about two-thirds of their lost weight within a year, and the cardiometabolic improvements they had gained drifted back toward baseline³. The mirror image is just as clear: in STEP 4, people who continued the drug maintained their loss while those switched to placebo regained it⁴, and the four-year SELECT data show weight loss largely sustained on continued treatment rather than rebounding⁵.

This is the crux. Wegovy manages weight rather than curing it, so for most people the realistic plan is indefinite use — which means the ~$500–$1,600/month is not a one-time expense but a standing line item, potentially for years. A drug that costs $1,500/month and works only while you take it is a very different purchase than a $1,500 one-time procedure. That is precisely why a monthly figure deserves more scrutiny than a sticker glance gives it — we line every telehealth provider up from the lowest published price upward, flagging which headline numbers are intro months, memberships or partial doses rather than the bill you would still be paying in year two. We unpack the regain evidence in detail in will you regain weight after stopping semaglutide?, and the lived experience in what happens when you stop semaglutide.

Why "worth it" splits by what you're treating

Here is the even-handed part: the same drug, at the same price, is a genuinely different value proposition depending on your indication.

For cardiovascular risk reduction or diabetes-adjacent metabolic disease, the value case is strongest. In the SELECT trial, semaglutide reduced major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in people with established cardiovascular disease and overweight or obesity but without diabetes⁶. When the drug is buying you a lower risk of a heart attack — not just a smaller waist — the recurring cost is being weighed against a hard clinical outcome, and many clinicians and patients judge that trade favorably. (Note: the cardiovascular indication and the diabetes brand are distinct from Wegovy's weight-management label; for the heart-benefit evidence see Wegovy & Ozempic heart benefits.)

For purely cosmetic weight loss — a person without obesity-related medical conditions who wants to lose a relatively modest amount — the value case is weakest. You are paying a high, indefinite price for an appearance goal, the weight returns if you stop, and you carry the side-effect and muscle-loss trade-offs the whole time. That does not make it "wrong," but it is the scenario where the cost-benefit math is hardest to defend, and where the indefinite-use reality bites hardest.

For obesity as a chronic disease (the on-label core: a BMI in the obese range, or overweight with a weight-related condition like hypertension, sleep apnea, or fatty liver), the value sits in between and leans positive — you are treating a medical condition with strong trial backing, and the ~15% loss meaningfully improves many of those conditions. This is the population the trials actually studied, and the one the label is written for².

So — is it worth it?

For most people the honest answer is "it depends, and mostly on two things": your indication and your ability to sustain the cost indefinitely. If you have cardiovascular disease or obesity-related medical conditions and can afford (or insure) ongoing treatment, the evidence makes a strong case that the benefit justifies the price. If you are chasing a cosmetic target, paying cash, and have not reckoned with the fact that stopping reverses the loss, the value proposition is much weaker and worth a hard second look. The drug is real, FDA-approved, and well-evidenced — that was never the question. The question is whether this benefit, at this recurring price, for this reason, is worth it to you. That is a conversation for a prescriber, run against your own budget and goals.

For the full evidence picture on what Wegovy does once you are on it, see our pillar, Semaglutide: How It Works, Results & Side Effects; to see how real-world experience lines up with the trials, see Wegovy reviews; and if you decide it is worth trying, our independent best semaglutide providers guide ranks legitimate options on price and oversight. And if you are comparing structured programs, see our honest Calibrate weight loss review and Found weight loss review.